ArticleFrontiers in neurology
Cerebellar hypoperfusion in anti-NF155 antibody-positive nodopathy: a retrospective case series using brain perfusion SPECT.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Anti-neurofascin-155 (NF155) antibody-positive nodopathy is a distinct autoimmune neuropathy characterized by sensory ataxia, tremor, and poor response to intravenous immunoglobulin (IVIg). Although classically considered a peripheral disorder, central nervous system (CNS) involvement has been suggested, but functional neuroimaging correlates remain unclear. Methods: We retrospectively analyzed seven male patients with NF155 antibody-positive nodopathy. Clinical and electrophysiological assessments were performed, and all patients underwent brain perfusion single-photon emission computed tomography (SPECT) using 123I-IMP iodoamphetamine. Imaging data were processed using three-dimensional stereotactic surface projection (3D-SSP) and compared to an age-matched database. Cerebellar hypoperfusion was defined as regional Results: The mean patient age was 39.0 ± 12.9 years, and mean disease duration was 5.0 ± 3.9 years. Tremor was documented in all patients at some point during the disease course and was predominantly postural or kinetic. Cerebellar hypoperfusion was identified in six patients (86%), involving the cerebellum bilaterally in most cases, with variable degrees of asymmetry across individuals. No correlation was found between hypoperfusion and disease duration or age. Conclusion: Cerebellar hypoperfusion was frequently observed in this single-center case series of anti-NF155 antibody-positive nodopathy. These findings are descriptive and hypothesis-generating, and compatible with a possible association between cerebellar perfusion abnormalities and tremor. Larger prospective studies are warranted to validate these observations and explore their clinical implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.